Clinical Trials Logo

Aicardi Goutieres Syndrome clinical trials

View clinical trials related to Aicardi Goutieres Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04731103 Completed - Clinical trials for Aicardi-Goutières Syndrome

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

AGS-RTI
Start date: August 24, 2022
Phase: Phase 2
Study type: Interventional

Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, which acts as a poison that damages the cells. The Investigators wish to treat AGS patients with drugs called reverse transcriptase inhibitors (RTIs), used to fight the HIV-1 virus that causes AIDS. The investigators will monitor the effect of treatment on interferon levels, and look at other markers which might give us clues to how the drugs are working. The trial is funded by the Medical Research Council, and involves experts based in Edinburgh, Birmingham, Manchester and Great Ormond Street Hospital.

NCT ID: NCT03921554 Completed - Clinical trials for Aicardi Goutieres Syndrome

JAK Inhibitor Treatment in AGS

Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production